Robert G Price

List of Publications by Year in Descending Order

15 papers	560 citations	9 h-index	18 g-index
18 ext. papers	757 ext. citations	5.1 avg, IF	3.81 L-index

#	Paper	IF	Citations
15	Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma.. *Respiratory Research*, **2022**, 23, 45	7.3	0
14	Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports. *Clinical and Translational Allergy*, **2021**, 11, e12067	5.2	0
13	Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. *Respiratory Research*, **2021**, 22, 144	7.3	7
12	Stopping continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). *European Respiratory Journal*, **2021**,	13.6	8
11	Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing. *Pharmaceutical Statistics*, **2021**, 20, 551-562	1	3
10	Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. *Clinical Therapeutics*, **2019**, 41, 2041-2056.e5	3.5	51
9	Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 1336-1342.e7	11.5	38
8	Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. *Allergy, Asthma and Clinical Immunology*, **2019**, 15, 37	3.2	18
7	Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis. *Respiratory Research*, **2019**, 20, 83	7.3	25
6	The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. *Allergy: European Journal of Allergy and Clinical Immunology*, **2019**, 74, 1716-1726	9.3	57
5	Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. *Pediatric Pulmonology*, **2019**, 54, 1957-1967	3.5	32
4	Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 1742-1751.e7	11.5	136
3	Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults **2018**,		2
2	Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. *Journal of Allergy and Clinical Immunology*, **2017**, 140, 1464-1466.e4	11.5	13
1	Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. *Clinical Therapeutics*, **2016**, 38, 2058-2070.e1	3.5	170